[{"address1": "900 Stewart Avenue", "address2": "Suite 301", "city": "Garden City", "state": "NY", "zip": "11530", "country": "United States", "phone": "516 665 8200", "website": "https://www.beyondair.net", "industry": "Medical Devices", "sector": "Healthcare", "longBusinessSummary": "Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.", "fullTimeEmployees": 107, "companyOfficers": [{"maxAge": 1, "name": "Mr. Steven Adam Lisi", "age": 52, "title": "CEO & Chairman of the Board", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 650000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael A. Gaul", "age": 68, "title": "Chief Operating Officer", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 400000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Amir  Avniel", "age": 49, "title": "Chief Executive Officer of NeuroNOS", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 495997, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas Quinton Larson", "age": 53, "title": "CFO, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 274955, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Edward  Barger", "title": "Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew R. Colin M.D.", "title": "Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David R. Webster", "age": 56, "title": "Chief Commercial Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John  Jett Ph.D.", "title": "Head of Research & Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Newman", "title": "Corporate Secretary", "fiscalYear": 2024, "totalPay": 250000, "exercisedValue": 0, "unexercisedValue": 595625}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 0.445, "open": 0.445, "dayLow": 0.4413, "dayHigh": 0.5045, "regularMarketPreviousClose": 0.445, "regularMarketOpen": 0.445, "regularMarketDayLow": 0.4413, "regularMarketDayHigh": 0.5045, "beta": -0.118, "forwardPE": -0.96, "volume": 224270, "regularMarketVolume": 224270, "averageVolume": 588326, "averageVolume10days": 730510, "averageDailyVolume10Day": 730510, "bid": 0.4737, "ask": 0.5785, "bidSize": 200, "askSize": 200, "marketCap": 34650048, "fiftyTwoWeekLow": 0.296, "fiftyTwoWeekHigh": 2.36, "priceToSalesTrailing12Months": 19.433565, "fiftyDayAverage": 0.39786, "twoHundredDayAverage": 1.00575, "currency": "USD", "enterpriseValue": 20226848, "floatShares": 17003248, "sharesOutstanding": 72187600, "sharesShort": 1350599, "sharesShortPriorMonth": 444132, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0187, "heldPercentInsiders": 0.16358, "heldPercentInstitutions": 0.36731997, "shortRatio": 1.63, "shortPercentOfFloat": 0.0211, "bookValue": 0.351, "priceToBook": 1.3675213, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -58348000, "trailingEps": -1.64, "forwardEps": -0.5, "enterpriseToRevenue": 11.344, "enterpriseToEbitda": -0.347, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "XAIR", "underlyingSymbol": "XAIR", "shortName": "Beyond Air, Inc.", "longName": "Beyond Air, Inc.", "firstTradeDateEpochUtc": 1528810200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "84c5f7c5-4229-3962-bff7-e86fa2577eb7", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.48, "targetHighPrice": 8.0, "targetLowPrice": 1.0, "targetMeanPrice": 3.75, "targetMedianPrice": 3.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 21374000, "totalCashPerShare": 0.459, "ebitda": -58358000, "totalDebt": 17701000, "quickRatio": 1.874, "currentRatio": 2.627, "totalRevenue": 1783000, "debtToEquity": 100.006, "revenuePerShare": 0.048, "returnOnAssets": -0.63484, "returnOnEquity": -2.19183, "freeCashflow": -28540376, "operatingCashflow": -49041000, "revenueGrowth": 10.576, "grossMargins": -0.78295, "operatingMargins": -19.88433, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]